Cargando…
Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities
Pancreatic ductal adenocarcinoma (PDAC) is one of the malignancies with the worst prognosis despite a decade of efforts. Up to eighty percent of patients are managed at late stages with metastatic disease, in part due to a lack of diagnosis. The effectiveness of PDAC therapies is challenged by the e...
Autores principales: | Dardare, Julie, Witz, Andréa, Merlin, Jean-Louis, Bochnakian, Agathe, Toussaint, Paul, Gilson, Pauline, Harlé, Alexandre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399337/ https://www.ncbi.nlm.nih.gov/pubmed/34451837 http://dx.doi.org/10.3390/ph14080740 |
Ejemplares similares
-
SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma
por: Dardare, Julie, et al.
Publicado: (2020) -
DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy
por: Dardare, Julie, et al.
Publicado: (2022) -
ESR1 Gene Mutations and Liquid Biopsy in ER-Positive Breast Cancers: A Small Step Forward, a Giant Leap for Personalization of Endocrine Therapy?
por: Betz, Margaux, et al.
Publicado: (2023) -
CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines
por: Witz, Andréa, et al.
Publicado: (2023) -
Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA)
por: Gilson, Pauline, et al.
Publicado: (2021)